HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Forecast & Target Price

View the latest analyst price targets and forecasts to stay informed on market expectations. Click here to open.

LXEO

Lexeo Therapeutics Inc

Last Close
Nov 27 • 04:00PM ET
7.83
Dollar change
+0.50
Percentage change
6.82 		%
Healthcare • Biotechnology • USA • NASD
Peers: CRSP QURE SRPT NTLA BEAM RARE BLUE EDIT SGMO ADVM
 | Held by: IWM VTI VXF IWO VTWO IWC VTWG IWN RSSL UWM
Scroll to Statements
IndexRUT P/E- EPS (ttm)-2.84 Insider Own27.96% Shs Outstand26.65M Perf Week27.94%
Market Cap276.57M Forward P/E- EPS next Y-3.01 Insider Trans-0.67% Shs Float23.82M Perf Month-21.46%
Income-86.60M PEG- EPS next Q-0.81 Inst Own73.88% Short Float10.47% Perf Quarter-32.62%
Sales0.00M P/S- EPS this Y74.84% Inst Trans13.38% Short Ratio6.10 Perf Half Y-51.21%
Book/sh4.21 P/B1.86 EPS next Y3.58% ROA-75.77% Short Interest2.49M Perf Year-34.42%
Cash/sh4.45 P/C1.76 EPS next 5Y- ROE-107.21% 52W Range5.77 - 22.33 Perf YTD-41.65%
Dividend Est.- P/FCF- EPS past 5Y- ROI-58.89% 52W High-64.94% Beta2.56
Dividend TTM- Quick Ratio5.95 Sales past 5Y19.69% Gross Margin- 52W Low35.70% ATR (14)0.78
Dividend Ex-Date- Current Ratio5.95 EPS Y/Y TTM- Oper. Margin0.00% RSI (14)51.36 Volatility8.09% 11.18%
Employees58 Debt/Eq0.07 Sales Y/Y TTM- Profit Margin- Recom1.14 Target Price22.29
Option/ShortNo / Yes LT Debt/Eq0.06 EPS Q/Q-18.20% Payout- Rel Volume0.56 Prev Close7.33
Sales Surprise- EPS Surprise-31.19% Sales Q/Q- EarningsNov 13 BMO Avg Volume408.86K Price7.83
SMA206.46% SMA50-7.63% SMA200-37.33% Trades Volume228,868 Change6.82%
Date Action Analyst Rating Change Price Target Change
Jun-13-24Initiated Robert W. Baird Outperform $28
Jun-06-24Initiated H.C. Wainwright Buy $22
Nov-28-23Initiated Stifel Buy $20
Nov-28-23Initiated RBC Capital Mkts Outperform $22
Nov-28-23Initiated Leerink Partners Outperform $19
Nov-28-23Initiated JP Morgan Overweight $20
Nov-28-23Initiated Chardan Capital Markets Buy $23
Nov-13-24 07:30AM
Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results
(GlobeNewswire)
Oct-30-24 06:14AM
Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer's Disease, at the Clinical Trials on Alzheimer's Disease (CTAD) Conference
(GlobeNewswire) -17.00%
Oct-22-24 07:30AM
Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Conference
(GlobeNewswire)
Sep-05-24 07:30AM
Lexeo Therapeutics to Participate in Upcoming Investor Conferences
(GlobeNewswire)
Aug-12-24 07:00AM
Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights
(GlobeNewswire)
11:03AM Loading…
Jul-16-24 11:03AM
Lexeo (LXEO) Down Despite Upbeat Rare Disease Gene Therapy Data
(Zacks)
Jul-15-24 04:17PM
Why Lexeo Therapeutics Collapsed 26%, Sacrificing A Breakout In Bearish Fashion
(Investor's Business Daily) -26.08%
10:11AM
Why Top 4% Biotech Stock Lexeo Therapeutics Just Gave Up A Breakout
(Investor's Business Daily)
06:36AM
Lexeo gene therapy shows signs of heart benefit in small study
(BioPharma Dive)
06:00AM
Lexeo Therapeutics Announces Positive Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy
(GlobeNewswire)
Jul-11-24 08:00AM
Lexeo Therapeutics Announces Investor Webcast to Report Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy on Monday, July 15, 2024
(GlobeNewswire) +6.08%
Jul-08-24 07:00AM
Lexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of Directors
(GlobeNewswire) +5.55%
May-14-24 12:00PM
What Makes Lexeo Therapeutics, Inc. (LXEO) a New Buy Stock
(Zacks)
09:55AM
Wall Street Analysts Think Lexeo Therapeutics, Inc. (LXEO) Could Surge 57.82%: Read This Before Placing a Bet
(Zacks)
May-09-24 07:00AM
Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights
(GlobeNewswire) +5.69%
07:30AM Loading…
May-07-24 07:30AM
Lexeo Therapeutics to Participate in Upcoming Investor Conferences
(GlobeNewswire)
Apr-22-24 07:30AM
Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy
(GlobeNewswire) +5.06%
Apr-16-24 07:30AM
Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich's Ataxia Cardiomyopathy
(GlobeNewswire)
Mar-13-24 04:22PM
Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing
(GlobeNewswire) +5.67% -5.43%
Mar-11-24 07:42AM
Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
(GlobeNewswire)
07:30AM
Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity Financing
(GlobeNewswire)
Feb-05-24 07:00AM
Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments
(GlobeNewswire)
Jan-03-24 07:00AM
Lexeo Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
(GlobeNewswire)
Dec-18-23 07:00AM
Lexeo Therapeutics Granted FDA Fast Track Designation and Orphan Drug Designation for LX2020, an AAV-Based Gene Therapy Candidate for PKP2 Arrhythmogenic Cardiomyopathy (ACM)
(GlobeNewswire) +8.71%
Dec-13-23 04:59AM
Lexeo Therapeutics Inc (LXEO) Reports Q3 2023 Financial Results and Advances Clinical Programs
(GuruFocus.com)
Dec-11-23 12:05PM
LXEO Stock Earnings: Lexeo Therapeutics Reported Results for Q3 2023
(InvestorPlace) -12.94%
07:00AM
Lexeo Therapeutics Reports Third Quarter 2023 Financial Results and Operational Highlights
(GlobeNewswire)
Nov-30-23 08:42AM
J.P. Morgan Recommends These 2 Strong Buy Stocks With Over 60% Upside Potential
(TipRanks)
Nov-02-23 09:51PM
Lexeo Therapeutics Announces Pricing of Initial Public Offering
(GlobeNewswire)
Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company, which engages in the development of therapies for hereditary and acquired diseases. The firm focuses on the medication of genetically defined cardiovascular diseases and sub-group of Alzheimer's disease. It offers LX2006 for the treatment of patients with Friedreich's ataxia, cardiomyopathy, and LX1001 for APOE4 homozygous patients with Alzheimer's disease. The company was founded by Ronald G. Crystal in February 2017 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CHOLMONDELEY PAULA HDirectorNov 25 '24Buy6.9915,000104,85230,627Nov 26 05:00 PM
Townsend Richard NolanChief Executive OfficerNov 11 '24Option Exercise2.332,5005,825123,195Nov 13 05:33 PM
Townsend Richard NolanChief Executive OfficerNov 11 '24Sale7.822,50019,557120,695Nov 13 05:33 PM
Townsend Richard NolanChief Executive OfficerOct 10 '24Option Exercise2.335,00011,650125,695Oct 15 01:45 PM
Townsend Richard NolanChief Executive OfficerOct 10 '24Sale8.105,00040,496120,695Oct 15 01:45 PM
Townsend Richard NolanChief Executive OfficerSep 10 '24Option Exercise2.335,00011,650125,695Sep 11 05:17 PM
Townsend Richard NolanChief Executive OfficerSep 10 '24Sale10.655,00053,274120,695Sep 11 05:17 PM
Richard Nolan TownsendDirectorSep 10 '24Proposed Sale10.7912,500134,875Sep 10 04:39 PM
Townsend Richard NolanChief Executive OfficerAug 12 '24Option Exercise2.335,00011,650125,695Aug 13 06:34 PM
Townsend Richard NolanChief Executive OfficerAug 12 '24Sale11.535,00057,634120,695Aug 13 06:34 PM
Townsend Richard NolanChief Executive OfficerJul 10 '24Option Exercise2.335,00011,650175,695Jul 12 04:55 PM
Townsend Richard NolanChief Executive OfficerJul 11 '24Sale17.0728,031478,409120,695Jul 12 04:55 PM
Townsend Richard NolanChief Executive OfficerJul 10 '24Sale16.5026,969444,979148,726Jul 12 04:55 PM
Townsend Richard NolanChief Executive OfficerJun 10 '24Option Exercise2.335,00011,650175,695Jun 12 05:00 PM
Townsend Richard NolanChief Executive OfficerJun 10 '24Sale17.655,00088,264170,695Jun 12 05:00 PM
Townsend Richard NolanChief Executive OfficerMay 13 '24Option Exercise2.335,00011,650175,695May 14 04:04 PM
Townsend Richard NolanChief Executive OfficerMay 13 '24Sale13.225,00066,093170,695May 14 04:04 PM
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • help • privacy • do not sell my data
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.